Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children

R.B. Belshe, F.K. Newman, E.L. Anderson, P.F. Wright, R.A. Karron, S. Tollefson, F.W. Henderson, H.C. Meissner, S. Madhi, D. Robertson, H. Marshall, R. Loh, Peter Sly, B. Murphy, J.M. Tatem, V. Randolph, J. Hackell, W. Gruber, T.F. Tsai

Research output: Contribution to journalArticlepeer-review

71 Citations (Scopus)

Abstract

We evaluated a combination respiratory syncytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, viral replication, and immunogenicity in doubly seronegative children 6 - 18 months old. RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 10(5) plaque-forming units of each per 0.5-mL dose and compared with monovalent vaccines or placebo. The virus shedding pattern of RSV was not different between monovalent RSV cpts-248/404 vaccine and combination vaccine. Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalent PIV3 vaccine. Both vaccines were immunogenic, and antibody responses were similar between the monovalent groups and the combination group. Combined RSV/ PV3 vaccine is feasible for simultaneous administration, and further studies are warranted.
Original languageEnglish
Pages (from-to)2096-2103
JournalJournal of Infectious Diseases
Volume190
Issue number12
DOIs
Publication statusPublished - 2004

Fingerprint

Dive into the research topics of 'Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children'. Together they form a unique fingerprint.

Cite this